Urinary Arsenic Species and CKD in a Taiwanese Population: A Case-Control Study

Yu-Mei Hsueh, Chi Jung Chung, Horng Sheng Shiue, Jin Bor Chen, Shou Shan Chiang, Mo Hsiung Yang, Cheng Wei Tai, Chien-Tien Su

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Background: Inorganic arsenic has been linked to decreased kidney function through oxidative damage. Arsenic methylation is believed to be a pathway for arsenic metabolism. Lycopene is an antioxidant that reduces oxidative stress; however, the association between urinary arsenic species, plasma lycopene level, and chronic kidney disease (CKD) has seldom been evaluated. Study Design: Case-control study. Setting & Participants: 125 patients with CKD and 229 controls were recruited from a hospital-based pool. Predictor: Urinary arsenic species and plasma lycopene level. Outcomes & Measurements: CKD was defined as estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m2, calculated by using the Modification of Diet in Renal Disease Study equation. Plasma lycopene was measured by means of high-performance liquid chromatography. Urinary arsenic species, including arsenite, arsenate, monomethylarsonic acid, and dimethylarsinic acid, were determined by means of high-performance liquid chromatography and hydride generator-atomic absorption spectrometry. Results: Lycopene level was associated positively with eGFR, and participants with a high serum lycopene level had a significant, inverse association with CKD (odds ratio, 0.41; 95% confidence interval, 0.21 to 0.81). Total arsenic level was associated significantly with CKD in a dose-response relationship, especially in participants with a total arsenic level greater than 20.74 compared with 11.78 μg/g creatinine or less (odds ratio, 4.34; 95% confidence interval, 1.94 to 9.69). Furthermore, participants with a high urinary total arsenic level or participants with a low percentage of dimethylarsinic acid had a positive association with CKD when their plasma lycopene level was low. Limitations: Because of the single spot evaluation of plasma antioxidants and urinary arsenic species and the small sample size, statistical significance should be interpreted with caution. Conclusions: This study shows that high urinary total arsenic or low plasma lycopene level is associated positively with CKD. Results suggest that the capacity for arsenic methylation may be associated with CKD in individuals who ingest low arsenic levels in drinking water and also have a low plasma lycopene level.

Original languageEnglish
Pages (from-to)859-870
Number of pages12
JournalAmerican Journal of Kidney Diseases
Volume54
Issue number5
DOIs
Publication statusPublished - Nov 2009

Fingerprint

Arsenic
Chronic Renal Insufficiency
Case-Control Studies
Population
Cacodylic Acid
Glomerular Filtration Rate
Methylation
Antioxidants
Odds Ratio
High Pressure Liquid Chromatography
Confidence Intervals
Diet Therapy
Kidney
lycopene
Drinking Water
Sample Size
Creatinine
Spectrum Analysis
Oxidative Stress

Keywords

  • Arsenic
  • arsenic methylation capacity
  • chronic kidney disease
  • lycopene

ASJC Scopus subject areas

  • Nephrology

Cite this

Urinary Arsenic Species and CKD in a Taiwanese Population : A Case-Control Study. / Hsueh, Yu-Mei; Chung, Chi Jung; Shiue, Horng Sheng; Chen, Jin Bor; Chiang, Shou Shan; Yang, Mo Hsiung; Tai, Cheng Wei; Su, Chien-Tien.

In: American Journal of Kidney Diseases, Vol. 54, No. 5, 11.2009, p. 859-870.

Research output: Contribution to journalArticle

Hsueh, Yu-Mei ; Chung, Chi Jung ; Shiue, Horng Sheng ; Chen, Jin Bor ; Chiang, Shou Shan ; Yang, Mo Hsiung ; Tai, Cheng Wei ; Su, Chien-Tien. / Urinary Arsenic Species and CKD in a Taiwanese Population : A Case-Control Study. In: American Journal of Kidney Diseases. 2009 ; Vol. 54, No. 5. pp. 859-870.
@article{058528894d1a46b48baece5d64103906,
title = "Urinary Arsenic Species and CKD in a Taiwanese Population: A Case-Control Study",
abstract = "Background: Inorganic arsenic has been linked to decreased kidney function through oxidative damage. Arsenic methylation is believed to be a pathway for arsenic metabolism. Lycopene is an antioxidant that reduces oxidative stress; however, the association between urinary arsenic species, plasma lycopene level, and chronic kidney disease (CKD) has seldom been evaluated. Study Design: Case-control study. Setting & Participants: 125 patients with CKD and 229 controls were recruited from a hospital-based pool. Predictor: Urinary arsenic species and plasma lycopene level. Outcomes & Measurements: CKD was defined as estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m2, calculated by using the Modification of Diet in Renal Disease Study equation. Plasma lycopene was measured by means of high-performance liquid chromatography. Urinary arsenic species, including arsenite, arsenate, monomethylarsonic acid, and dimethylarsinic acid, were determined by means of high-performance liquid chromatography and hydride generator-atomic absorption spectrometry. Results: Lycopene level was associated positively with eGFR, and participants with a high serum lycopene level had a significant, inverse association with CKD (odds ratio, 0.41; 95{\%} confidence interval, 0.21 to 0.81). Total arsenic level was associated significantly with CKD in a dose-response relationship, especially in participants with a total arsenic level greater than 20.74 compared with 11.78 μg/g creatinine or less (odds ratio, 4.34; 95{\%} confidence interval, 1.94 to 9.69). Furthermore, participants with a high urinary total arsenic level or participants with a low percentage of dimethylarsinic acid had a positive association with CKD when their plasma lycopene level was low. Limitations: Because of the single spot evaluation of plasma antioxidants and urinary arsenic species and the small sample size, statistical significance should be interpreted with caution. Conclusions: This study shows that high urinary total arsenic or low plasma lycopene level is associated positively with CKD. Results suggest that the capacity for arsenic methylation may be associated with CKD in individuals who ingest low arsenic levels in drinking water and also have a low plasma lycopene level.",
keywords = "Arsenic, arsenic methylation capacity, chronic kidney disease, lycopene",
author = "Yu-Mei Hsueh and Chung, {Chi Jung} and Shiue, {Horng Sheng} and Chen, {Jin Bor} and Chiang, {Shou Shan} and Yang, {Mo Hsiung} and Tai, {Cheng Wei} and Chien-Tien Su",
year = "2009",
month = "11",
doi = "10.1053/j.ajkd.2009.06.016",
language = "English",
volume = "54",
pages = "859--870",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Urinary Arsenic Species and CKD in a Taiwanese Population

T2 - A Case-Control Study

AU - Hsueh, Yu-Mei

AU - Chung, Chi Jung

AU - Shiue, Horng Sheng

AU - Chen, Jin Bor

AU - Chiang, Shou Shan

AU - Yang, Mo Hsiung

AU - Tai, Cheng Wei

AU - Su, Chien-Tien

PY - 2009/11

Y1 - 2009/11

N2 - Background: Inorganic arsenic has been linked to decreased kidney function through oxidative damage. Arsenic methylation is believed to be a pathway for arsenic metabolism. Lycopene is an antioxidant that reduces oxidative stress; however, the association between urinary arsenic species, plasma lycopene level, and chronic kidney disease (CKD) has seldom been evaluated. Study Design: Case-control study. Setting & Participants: 125 patients with CKD and 229 controls were recruited from a hospital-based pool. Predictor: Urinary arsenic species and plasma lycopene level. Outcomes & Measurements: CKD was defined as estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m2, calculated by using the Modification of Diet in Renal Disease Study equation. Plasma lycopene was measured by means of high-performance liquid chromatography. Urinary arsenic species, including arsenite, arsenate, monomethylarsonic acid, and dimethylarsinic acid, were determined by means of high-performance liquid chromatography and hydride generator-atomic absorption spectrometry. Results: Lycopene level was associated positively with eGFR, and participants with a high serum lycopene level had a significant, inverse association with CKD (odds ratio, 0.41; 95% confidence interval, 0.21 to 0.81). Total arsenic level was associated significantly with CKD in a dose-response relationship, especially in participants with a total arsenic level greater than 20.74 compared with 11.78 μg/g creatinine or less (odds ratio, 4.34; 95% confidence interval, 1.94 to 9.69). Furthermore, participants with a high urinary total arsenic level or participants with a low percentage of dimethylarsinic acid had a positive association with CKD when their plasma lycopene level was low. Limitations: Because of the single spot evaluation of plasma antioxidants and urinary arsenic species and the small sample size, statistical significance should be interpreted with caution. Conclusions: This study shows that high urinary total arsenic or low plasma lycopene level is associated positively with CKD. Results suggest that the capacity for arsenic methylation may be associated with CKD in individuals who ingest low arsenic levels in drinking water and also have a low plasma lycopene level.

AB - Background: Inorganic arsenic has been linked to decreased kidney function through oxidative damage. Arsenic methylation is believed to be a pathway for arsenic metabolism. Lycopene is an antioxidant that reduces oxidative stress; however, the association between urinary arsenic species, plasma lycopene level, and chronic kidney disease (CKD) has seldom been evaluated. Study Design: Case-control study. Setting & Participants: 125 patients with CKD and 229 controls were recruited from a hospital-based pool. Predictor: Urinary arsenic species and plasma lycopene level. Outcomes & Measurements: CKD was defined as estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m2, calculated by using the Modification of Diet in Renal Disease Study equation. Plasma lycopene was measured by means of high-performance liquid chromatography. Urinary arsenic species, including arsenite, arsenate, monomethylarsonic acid, and dimethylarsinic acid, were determined by means of high-performance liquid chromatography and hydride generator-atomic absorption spectrometry. Results: Lycopene level was associated positively with eGFR, and participants with a high serum lycopene level had a significant, inverse association with CKD (odds ratio, 0.41; 95% confidence interval, 0.21 to 0.81). Total arsenic level was associated significantly with CKD in a dose-response relationship, especially in participants with a total arsenic level greater than 20.74 compared with 11.78 μg/g creatinine or less (odds ratio, 4.34; 95% confidence interval, 1.94 to 9.69). Furthermore, participants with a high urinary total arsenic level or participants with a low percentage of dimethylarsinic acid had a positive association with CKD when their plasma lycopene level was low. Limitations: Because of the single spot evaluation of plasma antioxidants and urinary arsenic species and the small sample size, statistical significance should be interpreted with caution. Conclusions: This study shows that high urinary total arsenic or low plasma lycopene level is associated positively with CKD. Results suggest that the capacity for arsenic methylation may be associated with CKD in individuals who ingest low arsenic levels in drinking water and also have a low plasma lycopene level.

KW - Arsenic

KW - arsenic methylation capacity

KW - chronic kidney disease

KW - lycopene

UR - http://www.scopus.com/inward/record.url?scp=70350132295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350132295&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2009.06.016

DO - 10.1053/j.ajkd.2009.06.016

M3 - Article

C2 - 19682779

AN - SCOPUS:70350132295

VL - 54

SP - 859

EP - 870

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 5

ER -